Skip to main content
      Real-world T2T strategy from MONITOR-PsA cohort:
      🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' res

      sheila RHEUMarampa

      2 weeks ago
      Real-world T2T strategy from MONITOR-PsA cohort: 🎯 At 48 weeks - 33.6% (49/146) of pts achieved PASDAS 'moderate' response & 37% (54/146) achieved a 'good' response This was close to the T2T outcomes of the TICOPA trial Adapt a T2T approach in PsA tx #ACR25 @RheumNow Abs0572 https://t.co/FPiFIiO8Oe
      Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. R

      Richard Conway RichardPAConway

      2 weeks ago

      Albach et al. CAR T-cells in D2T RA. 6 patients. Safety looks ok. ACR20 in 4/6, ACR50 in 2/6. ACPA and RF disappeared. Results maybe not as positive as we might have anticipated? @RheumNow #ACR25 Abstr#471 https://t.co/TaEVWiWsNm

      SELECT-GCA (upadacitinib in GCA for 52w)
      we hoped it might have ongoing effect post-cessation

      Do we need to continue up

      David Liew drdavidliew

      2 weeks ago
      SELECT-GCA (upadacitinib in GCA for 52w) we hoped it might have ongoing effect post-cessation Do we need to continue upa? Extension data (second year) flare survival curves are clear: continuing upa far outperforms placebo It seems >2y toci/upa for GCA #ACR25 ABST0776 @RheumNow https://t.co/uJA3uQyWxb
      #0776
      In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO,

      Mrinalini Dey DrMiniDey

      2 weeks ago
      #0776 In the 2-yr SELECT-GCA trial, continued upadacitinib 15mg maintained remission in 69% vs 29% who switched to PBO, cutting flare risk by 90% and reducing steroid exposure by ~1g. No new safety signals in older adults (mean 71yrs). @RheumNow #ACR25 https://t.co/KC9sm3ic3q
      RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. A

      Dr. John Cush RheumNow

      2 weeks ago
      RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
      Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per

      Richard Conway RichardPAConway

      2 weeks ago

      Singla et al. In secukinumab phase 3 trials, fungal (inc candida) infections uncommon. 5.51 for sec vs 3.39 for PBO per 100PY. @RheumNow #ACR25 Abstr#585 https://t.co/g78zUsxD5a

      Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90%

      Richard Conway RichardPAConway

      2 weeks ago
      Schmidt et al. 2 year results of SELECT-GCA, upadacitinib in GCA. Remission 69% if upa continued vs 29% if stopped. 90% lower risk of flare, 1G less steroid @RheumNow #ACR25 Abstr#0776 #ACRBest https://t.co/MgRo7kIgIw
      Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective

      @RheumNow #ACR25 http

      Brian Jaros, MD Dr_Brian_MD

      2 weeks ago
      Not all inflammatory nasal lesions are vasculitis! Dr. Zacharek presents from the ENT perspective @RheumNow #ACR25 https://t.co/TJ4d56oBaJ
      Post-hoc PEXIVAS study, estimating risk of relapse from baseline variables

      Lotsa fancy stats, mostly corroborated know

      Mike Putman EBRheum

      2 weeks ago
      Post-hoc PEXIVAS study, estimating risk of relapse from baseline variables Lotsa fancy stats, mostly corroborated known risk factors, but model predicted relapse reasonably well! Probably useful for approach to monitoring... mayyybe treatment? #ACR25 @RheumNow #Abstr0722 https://t.co/XI9y8KgDNR
      Statins and SLE: To add or not to add? 💊
      Abstract #0599: In an emulated target trial of patients with SLE, statin use

      Akhil Sood MD, MS AkhilSoodMD

      2 weeks ago
      Statins and SLE: To add or not to add? 💊 Abstract #0599: In an emulated target trial of patients with SLE, statin users vs non-users had significantly⬇️ risk of all-cause death in both ITT & per-protocol analyses. - No significant differences in MACE or ESKD. @RheumNow #ACR25
      Mease et al. Sometimes perspective is all important! We worry about apremilast causing GI effects, anorexia, weight loss

      Richard Conway RichardPAConway

      2 weeks ago
      Mease et al. Sometimes perspective is all important! We worry about apremilast causing GI effects, anorexia, weight loss. Here we see reported benefits for weight loss and HbA1c. @RheumNow #ACR25 Abstr#581 https://t.co/CJjS0VZxWH
      Tracking RA disease activity got a measurable boost in the VA: a 3-month multimodal rollout (feedback, EHR tools, just-i

      Jiha Lee JihaRheum

      2 weeks ago
      Tracking RA disease activity got a measurable boost in the VA: a 3-month multimodal rollout (feedback, EHR tools, just-in-time lists) raised DAM documentation up to 10%. Small structural changes, big data gains. @RheumNow #ACR25 Abstract#0221
      Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA)

      Pts in remission re-randomized at wk52

      Higher maintenance of remission

      Mike Putman EBRheum

      2 weeks ago
      Plenary 1: SELECT-GCA (RCT, UPA vs PLBO in GCA) Pts in remission re-randomized at wk52 Higher maintenance of remission in pts who continued UPA15 (69%) vs switchers from UPA15->PLBO (29%) Argues strongly for continuing tx in GCA for >1yr! @RheumNow #ACR25 Ab#0776 #ACRBest https://t.co/exmmIcpgbP
      tRNA-derived RNA (tDR-1), circulating microbial RNA

      Associated w/ reduction in risk of RA conversion in asymptomatic CC

      Aurelie Najm AurelieRheumo

      2 weeks ago
      tRNA-derived RNA (tDR-1), circulating microbial RNA Associated w/ reduction in risk of RA conversion in asymptomatic CCP+ individuals (60 vs. 120+ ctrls), ‼️ tDR-1 alone over performs prediction model w/ smoking shared episode and RF w/ AUC 0.86 What is the mechanism? tDR-1 https://t.co/fuyk4NeOyA
      Ribeiro et al. Case series of combination bDMARD/tsDMARD in PsA from Toronto. 24 patients, median just over a year follo

      Richard Conway RichardPAConway

      2 weeks ago
      Ribeiro et al. Case series of combination bDMARD/tsDMARD in PsA from Toronto. 24 patients, median just over a year follow-up. Appear effective, especially for objective skin and joint measures. No major safety concerns but short follow-up to date. @RheumNow #ACR25 Abstr#565 https://t.co/Zk3odT2EX2
      ×